Pneumeric, Inc., Manufacturers of the CAPNOSPOT™ Medical Device, Announce Nearly $40,000 Raised from Its Equity Crowdfunding Campaign

Rochester, MN - February 10, 2023 - Pneumeric Inc., developers of the Capnospot™ - A disposable medical device that allows visual detection of carbon dioxide during treatment of a collapsed lung with needle decompression, has raised nearly $40,000 from 124 investors through its recently launched equity crowdfunding campaign.

These funds build on the $1.2 million Pneumeric has already raised from angel groups and medical professionals.

A third of preventable trauma deaths result from a collapsed lung (otherwise known as a tension pneumothorax) brought about by blunt trauma. During needle decompression, medical professionals confirm the procedure's success by listening for an audible “gush” of carbon dioxide from the chest cavity — a procedure that can be prone to human error in stressful and noisy environments. Pneumeric’s Capnospot changes the diagnostic procedure from audible to visual by detecting carbon dioxide that changes colorimetric paper from blue to yellow.

"When we were doing needle decompressions in the trauma bay, we realized we were basically guessing if we had done the procedure correctly," says CEO and Chief Medical Officer Johnathon Aho, MD, Ph.D. "We knew we could make a simple, inexpensive device to supply first responders and trauma casualty caregivers with rapid visual feedback that would save lives."

For more information about Pneumeric and its equity crowdfunding campaign, visit their MicroVentures page.

About Pneumeric, Inc: 

Pneumeric™ is a leading medical device manufacturer that has developed the Capnospot™, a colorimetric capnography device with the potential to provide visual, objective, real-time feedback about needle placement during decompression. Specifically, the device indicates the presence of carbon dioxide in the air from the decompressed pneumothorax, which allows for accurate needle placement. Pneumeric aims to advance emergency point-of-care therapy for confirmation of tension pneumothorax decompression while creating value for its patients, clinicians, and hospital administrators.